Bart A Westerman
Overview
Explore the profile of Bart A Westerman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
2065
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van der Gaag S, Jordens T, Yaqub M, Grijseels R, van Valkengoed D, de Langen E, et al.
CPT Pharmacometrics Syst Pharmacol
. 2025 Feb;
PMID: 40009553
Osimertinib, a tyrosine kinase inhibitor (TKI), treats non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. However, its efficacy may vary due to heterogeneous drug distribution, assessable...
2.
Cornelissen F, He Z, Ciputra E, de Haas R, Beumer-Chuwonpad A, Noske D, et al.
Mol Oncol
. 2024 Oct;
19(3):716-740.
PMID: 39417309
Glioblastoma (GB), the most common and aggressive brain tumor, demonstrates intrinsic resistance to current therapies, resulting in poor clinical outcomes. Cancer progression can be partially attributed to the deregulation of...
3.
Kucukosmanoglu A, van der Borden C, de Boer L, Verhaak R, Noske D, Wurdinger T, et al.
Mol Oncol
. 2024 May;
18(10):2407-2422.
PMID: 38757376
Genetic heterogeneity in tumors can show a remarkable selectivity when two or more independent genetic events occur in the same gene. This phenomenon, called composite mutation, points toward a selective...
4.
Kucukosmanoglu A, Scoarta S, Houweling M, Spinu N, Wijnands T, Geerdink N, et al.
Clin Cancer Res
. 2024 Apr;
30(8):1685-1695.
PMID: 38597991
Purpose: Combination therapies are a promising approach for improving cancer treatment, but it is challenging to predict their resulting adverse events in a real-world setting. Experimental Design: We provide here...
5.
Malta T, Sabedot T, Morosini N, Datta I, Garofano L, Vallentgoed W, et al.
Cancer Res
. 2023 Dec;
84(5):741-756.
PMID: 38117484
Significance: Standard treatments are related to loss of DNA methylation in IDHmut glioma, resulting in epigenetic activation of genes associated with tumor progression and alterations in the microenvironment that resemble...
6.
Giczewska A, Pastuszak K, Houweling M, Abdul K, Faaij N, Wedekind L, et al.
Neurooncol Adv
. 2023 Dec;
5(1):vdad134.
PMID: 38047207
Background: In recent years, drug combinations have become increasingly popular to improve therapeutic outcomes in various diseases, including difficult to cure cancers such as the brain cancer glioblastoma. Assessing the...
7.
van Garderen K, Vallentgoed W, Lavrova A, Niers J, de Leng W, Hoogstrate Y, et al.
Neurooncol Adv
. 2023 Nov;
5(1):vdad149.
PMID: 38024241
Background: The T2-FLAIR mismatch sign is defined by signal loss of the T2-weighted hyperintense area with Fluid-Attenuated Inversion Recovery (FLAIR) on magnetic resonance imaging, causing a hypointense region on FLAIR....
8.
Kanev G, Zhang Y, Kooistra A, Bender A, Leurs R, Bailey D, et al.
PLoS Comput Biol
. 2023 Sep;
19(9):e1011301.
PMID: 37669273
Many therapies in clinical trials are based on single drug-single target relationships. To further extend this concept to multi-target approaches using multi-targeted drugs, we developed a machine learning pipeline to...
9.
Houweling M, Giczewska A, Abdul K, Nieuwenhuis N, Kucukosmanoglu A, Pastuszak K, et al.
Neurooncol Adv
. 2023 Jul;
5(1):vdad073.
PMID: 37455945
Background: IDH-wildtype glioblastoma (GBM) is a highly malignant primary brain tumor with a median survival of 15 months after standard of care, which highlights the need for improved therapy. Personalized...
10.
Cornelissen F, Markert G, Deutsch G, Antonara M, Faaij N, Bartelink I, et al.
J Med Chem
. 2023 May;
66(11):7253-7267.
PMID: 37217193
The blood-brain barrier (BBB) represents a major obstacle to delivering drugs to the central nervous system (CNS), resulting in the lack of effective treatment for many CNS diseases including brain...